Heightened but variable COVID-19 risks for patients with cancer
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19
Four years into the coronavirus disease 2019 (COVID-19) pandemic, multiple studies have agreed that patients with cancer are more susceptible to COVID-19 infection and have a higher risk of worse outcomes than the general population. Large cohort studies have revealed plenty of nuances, however, while raising additional questions in need of better answers. Some cancer types, such as hematologic malignancies, have been associated with a higher risk of poor COVID-19 outcomes, as have some treatment types, such as recent cytotoxic chemotherapies, as well as a long list of other demographic factors and comorbidities. Researchers are just starting to investigate the added danger of long COVID-19. The data, however, have also provided some reassurances, says Noha Sharafeldin, MD, PhD, MSc, an assistant professor of medicine at the University of Alabama at Birmingham and an associate scientist at the university’s O’Neal Comprehensive Cancer Center. One of the most notable findings is that vaccination against the SARS-CoV-2 virus can reduce the risk of severe infection even among those with hematologic malignancies.
https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncy.22791 2024